Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP CoV-2: Treatment of non-severe COVID-19 and chemoprophylaxis of contacts
2020-001031-27Phase 3Active
- Sponsor
- Frazier Life Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of darunavir, cobicistat and hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Frazier Life Sciences. Primary endpoint: Transmissibility of SARS-CoV-2 within clusters. Started Apr 2020; status: active.
02
Drugs
darunavircobicistathydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001031-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001031-27.